生血合剂治疗老年再生障碍性贫血的临床研究

为观察生血合剂治疗老年再生障碍性贫血(简称再障)的临床疗效,探讨疗效机理,62例患者随机分为治疗组(32例)和对照组(30例).治疗组中脾肾阳虚型用生血I号合剂、脾肾阴虚型用生血Ⅱ号合剂;对照组30例用康力龙.疗程3个月.结果治疗组基本治愈6例、缓解9例、明显进步12例、无效5例,总有效率84.38%,治愈缓解46.88%,明显优于对照组(P＜0.05),且未见肝损等不良反应.治疗组患者症状改善,外周血象明显升高,T淋巴细胞亚群比例趋向正常,自然杀伤细胞活性(NKa)增加,白介素-2(IL-2)产生减少,骨髓增生程度明显好转,均有统计学意义(P＜0.05,P＜0.01).提示生血合剂治疗老年再障疗效良好,安全无毒,其疗效机制可能是通过调整免疫,改善骨髓微环境,促进造血功能的恢复来实现的.

Clinical Study of "Blood-Producing Mixture" in Treating Senile Aplastic Anemia

To observe the clinical efficacy of "Blood-Producing Mixture" in the treatment of senile aplastic anemia,62 cases were randomized into two groups:treatment group with 32 cases treated by No.1 "Blood-Producing Mixture" for those of spleen-kidney yang-deficiency and No.2 "Blood-Producing Mixture" for those of spleen-kidney yin-deficiency,and control group with 30 cases treated by Stanozolol.Results showed basic cure in 6 cases,remission in 9 cases,marked improvement in 12 cases and failure in 5 cases,and the total effective rate was 84.38%,cure and remission rate 46.88% and no negative effects in treatment group,higher than those in control group ( P <0.05).In treatment group,the clinical symptoms improved,peripheral blood count increasing,subsets of T lymphocyte tending to normalize,the activity of natural kill cell increasing,IL-2 reducing,production of bone marrow improving,with striking differences.